Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Apr;38(4):901–904. doi: 10.1128/aac.38.4.901

Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia.

P Saux 1, C Martin 1, M N Mallet 1, L Papazian 1, B Bruguerolle 1, P De Micco 1, F Gouin 1
PMCID: PMC284567  PMID: 8031070

Abstract

The aim of the study was to evaluate the penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia. For this purpose, in each patient studied, simultaneous serial blood and bronchial secretion samples were obtained over a 12-h period on days 2 and 4. Eight patients were included in the study. Ciprofloxacin was given at a dose of 200 mg over 30 min by using an automatic pump. Ciprofloxacin was measured by high-performance liquid chromatography. Peak levels of drug in serum were 2.95 +/- 1 mg/liter on day 2 and 2.43 +/- 0.7 mg/liter on day 4. Peak and trough levels in bronchial secretions were 0.95 +/- 0.51 and 0.21 +/- 0.12 mg/liter, respectively, on day 2 and 0.76 +/- 0.17 and 0.18 +/- 0.14 mg/liter, respectively, on day 4. The ratios of peak concentrations in bronchial secretions/serum were 0.32 +/- 0.11 and 0.33 +/- 0.06 on days 2 and 4, respectively. The ratios of the area under the concentration-time curve from 0 to 12 h (AUC0-12) for bronchial secretions/those for serum were 0.66 +/- 0.40 and 0.55 +/- 0.30 on days 2 and 4, respectively. A significant positive correlation was found on day 4 between the AUC0-12 for serum and the AUC0-12 for bronchial secretions. No significant correlations were found between peak values in serum and bronchial secretions.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry A. L., Jones R. N., Thornsberry C., Ayers L. W., Gerlach E. H., Sommers H. M. Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid. Antimicrob Agents Chemother. 1984 May;25(5):633–637. doi: 10.1128/aac.25.5.633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bergamini T. M., Polk H. C., Jr The importance of tissue antibiotic activity in the prevention of operative wound infection. J Antimicrob Chemother. 1989 Mar;23(3):301–313. doi: 10.1093/jac/23.3.301. [DOI] [PubMed] [Google Scholar]
  3. Bergogne-Berezin E. Penetration of antibiotics into the respiratory tree. J Antimicrob Chemother. 1981 Sep;8(3):171–174. doi: 10.1093/jac/8.3.171. [DOI] [PubMed] [Google Scholar]
  4. Bergogne-Bérézin E., Berthelot G., Even P., Stern M., Reynaud P. Penetration of ciprofloxacin into bronchial secretions. Eur J Clin Microbiol. 1986 Apr;5(2):197–200. doi: 10.1007/BF02013986. [DOI] [PubMed] [Google Scholar]
  5. Berré J., Thys J. P., Husson M., Gangji D., Klastersky J. Penetration of ciprofloxacin in bronchial secretions after intravenous administration. J Antimicrob Chemother. 1988 Oct;22(4):499–504. doi: 10.1093/jac/22.4.499. [DOI] [PubMed] [Google Scholar]
  6. Davies B. I., Maesen F. P., Baur C. Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. Eur J Clin Microbiol. 1986 Apr;5(2):226–231. doi: 10.1007/BF02013995. [DOI] [PubMed] [Google Scholar]
  7. Fraschini F., Braga P. C., Cosentina R., Salvini P., Cortelazzi R., Scarpazza G., Scaglione F., Trazzi R., Odero A. Ciprofloxacin: multiple-dose pharmacokinetic and clinical results in patients with hypercrinic bronchopulmonary diseases. Int J Clin Pharmacol Res. 1987;7(1):63–71. [PubMed] [Google Scholar]
  8. Goldfarb J., Stern R. C., Reed M. D., Yamashita T. S., Myers C. M., Blumer J. L. Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. Am J Med. 1987 Apr 27;82(4A):174–179. [PubMed] [Google Scholar]
  9. Honeybourne D., Wise R., Andrews J. M. Ciprofloxacin penetration into lungs. Lancet. 1987 May 2;1(8540):1040–1040. doi: 10.1016/s0140-6736(87)92315-4. [DOI] [PubMed] [Google Scholar]
  10. Hoogkamp-Korstanje J. A., Klein S. J. Ciprofloxacin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1986 Sep;18(3):407–413. doi: 10.1093/jac/18.3.407. [DOI] [PubMed] [Google Scholar]
  11. Hopf G., Böcker R., Estler C. J., Radtke H. J., Floh W. Concentration of ciprofloxacin in human serum, lung and pleural tissues and fluids during and after lung surgery. Infection. 1988;16(1):29–30. doi: 10.1007/BF01646928. [DOI] [PubMed] [Google Scholar]
  12. Iliadis A., Brown A. C., Huggins M. L. APIS: a software for model identification, simulation and dosage regimen calculations in clinical and experimental pharmacokinetics. Comput Methods Programs Biomed. 1992 Aug;38(4):227–239. doi: 10.1016/0169-2607(92)90103-e. [DOI] [PubMed] [Google Scholar]
  13. LeBel M., Bergeron M. G., Vallée F., Fiset C., Chassé G., Bigonesse P., Rivard G. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. Antimicrob Agents Chemother. 1986 Aug;30(2):260–266. doi: 10.1128/aac.30.2.260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Marchbanks C. R., McKiel J. R., Gilbert D. H., Robillard N. J., Painter B., Zinner S. H., Dudley M. N. Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection. Antimicrob Agents Chemother. 1993 Sep;37(9):1756–1763. doi: 10.1128/aac.37.9.1756. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Niederman M. S., Mantovani R., Schoch P., Papas J., Fein A. M. Patterns and routes of tracheobronchial colonization in mechanically ventilated patients. The role of nutritional status in colonization of the lower airway by Pseudomonas species. Chest. 1989 Jan;95(1):155–161. doi: 10.1378/chest.95.1.155. [DOI] [PubMed] [Google Scholar]
  16. Pedersen S. S., Jensen T., Hvidberg E. F. Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. J Antimicrob Chemother. 1987 Oct;20(4):575–583. doi: 10.1093/jac/20.4.575. [DOI] [PubMed] [Google Scholar]
  17. Peloquin C. A., Cumbo T. J., Nix D. E., Sands M. F., Schentag J. J. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch Intern Med. 1989 Oct;149(10):2269–2273. [PubMed] [Google Scholar]
  18. Reeves D. S., Bywater M. J., Holt H. A., White L. O. In-vitro studies with ciprofloxacin, a new 4-quinolone compound. J Antimicrob Chemother. 1984 Apr;13(4):333–346. doi: 10.1093/jac/13.4.333. [DOI] [PubMed] [Google Scholar]
  19. Smith M. J., White L. O., Bowyer H., Willis J., Hodson M. E., Batten J. C. Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis. Antimicrob Agents Chemother. 1986 Oct;30(4):614–616. doi: 10.1128/aac.30.4.614. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES